ARCHIVE OF OLDER REPORTS AND DEVELOPMENTS

APRIL 1996 to Fall 1998

• Discontinuing PCP Prophylaxis - Revised with Update From IDSA Nov12-15

• Abacavir: Accelerated Approval Recommended 7-2 by Panel Vote

• Remune + HAART 32 Week Update Announced

• Adefovir Dipivoxil aka PMEA (Preveon)

• Glaxo Wellcome announced about Oct 16 that they filed an application for accelerated approva (NDA) with the FDA for amprenavir, their new protease inhibitor...

• Norvir Abbott Meeting by Jules Levin

• Restoring the Immune System by Dr Fred Valentine, with some comments by Jules Levin

• A First Report in a Series on Resistance Testing; including a Geneva Report on Transmission of Protease Resistant Virus

• Efavirenz (Sustiva) Approved by FDA - Information on Sustiva

• Indinavir+Ritonavir;
  New Merck 2nd Generation Protease Inhibitor;
  Dr. Don Kotler on Lipodystrophy

• Crixivan Twice a day studies discontinued:
  Indinavir BID: Additional Applications - NNRTIs, Double Protease; and, a Brief Discussion of Salvage Therapy Approaches & Preventing Failure
  Important updated PK data on Amprenavir, Indinavir, and Efavirenz.

• Amprenavir expanded access program announced today

• Ultra-Sensitive Test Consensus Statement to the FDA

• T-20 Study Started

• Dietary suggestions for taking Ritonavir Liquid

• Jules Levin to speak on WNYC, AM 8:20,  Thursday, August 27, 1998-12 Noon!!

• Commercial Availability of Phenotypic Resistance Testing

• Protease Inhibitor and Viral Load Strategy Update a ten-part report (04/28/98)

• Salvage Therapies Starting: Read to Call as Soon as Possible!

• NRTI Report (04/28/98)

• PMPA (04/21/98)

• Early Combination Anitretroviral Therapy - First Report on Viral Kinetics and Control of Viral Replication in Children (04/21/98)

• NNRTI update: Reports on Efavirenz (EFV); NNRTI Resistance; and Nevirapine (NVP) (04/12/98)

• Efavirenz (EFV) Reports  includes PK effect of EFV on 141W94; 60 week data on EFV + Indinavir; 24 week data on EFV + AZT/3TC; and EFV CSF Levels in Monkeys (04/12/98)

• NNRTI Resistance Report (O4/12/98)

• T-20: A Fusion Inhibitor (03/12/98)
  pdf

• 1592U89 --A New Antiviral For HIV in Development (4/22/96) Glaxo Wellcome's nucleoside reverse transcriptase inhibitor in early studies.
  pdf

• Drug Interactions with Norvir (ritonavir) (4/10/96) table of contraindicated drugs and equivalents. If you don't have a browser that allows tables, view list file. See also Novir dosing up schedule.
  pdf